Physician profile
Mark A Durback
NPI 1689615601
$5,827.89
in general payments reported to CMS, 2019-2025
26 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,614 · 2020: $584 · 2021: $835 · 2022: $1,577 · 2023: $1,217.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,158 · Education: $59.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,157.50 |
| Education | $59.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $854.52 | 2019-2023 | Tremfya, Simponi Aria, Stelara |
| Ucb, INC. | $837.57 | 2019-2023 | Cimzia |
| Glaxosmithkline, LLC. | $668.30 | 2019-2023 | Benlysta |
| Abbvie INC. | $513.89 | 2019-2023 | Rinvoq |
| Actelion Pharmaceuticals US, INC. | $420.10 | 2019-2023 | Uptravi, Opsumit |
| Pfizer INC. | $348.25 | 2019-2023 | |
| Amgen INC. | $338.16 | 2019-2023 | Enbrel, Amjevita |
| Novartis Pharmaceuticals Corporation | $325.50 | 2019-2023 | |
| Mallinckrodt Hospital Products INC. | $302.91 | 2020-2023 | Acthar |
| Astrazeneca Pharmaceuticals Lp | $290.95 | 2021-2023 | Saphnelo |
| Genzyme Corporation | $173.24 | 2019-2020 | |
| Radius Health, INC. | $130.63 | 2019-2023 | Tymlos |
| Celgene Corporation | $114.44 | 2019 | |
| Genentech USA, INC. | $94.37 | 2019-2023 | Actemra |
| Fresenius Kabi USA, LLC | $71.87 | 2023 | Idacio |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $66.85 | 2019-2023 | Cyltezo |
| Horizon Therapeutics Plc | $47.61 | 2022 | |
| Sobi, INC | $46.19 | 2019 | |
| Pacira Therapeutics, INC. | $40.11 | 2019 | |
| Alexion Pharmaceuticals, INC. | $25.66 | 2019 | |
| Lilly USA, LLC | $24.61 | 2023 | Taltz |
| Mallinckrodt Enterprises LLC | $23.59 | 2019 | |
| Ani Pharmaceuticals, INC. | $21.90 | 2022 | |
| Aurinia Pharma U.S., INC. | $19.46 | 2021 | |
| Avion Pharmaceuticals | $14.98 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $12.23 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Durback listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.